How and where to order Avelox (Moxifloxacin) 400 mg tablets or capsules online on Respiratory Tract Infection Alert website:
|Prices:||from $2.25 per pill
|Discount:||10% coupon: MSD10
|Forms:||Moxifloxacin (Avelox) 400 mg tablets
|Type:||Moxifloxacin brand, Avelox generic
|Payment:||Visa, MasterCard, AmEx, E-Check (ACH), Bitcoin
|Delivery:||Regular and express mail service
|Shipping:||Worldwide, including USA, UK, Europe, Canada, Australia
Moxifloxacin (trade names include Avelox, Mediflox, Zymox, Avalox, Actira, Izilox, Moxeza, Moxicip, Octegra, Proflox, Vigamox) is a broad spectrum quinolone antibacterial medication from fluoroquinolones pharmacological group. This medicine is used for the treatment and prophylaxis of various kinds of infections such as complicated and uncomplicated skin, skin structure, soft tissue, eyes, intra-abdominal, respiratory tract infections. Indication include pneumonia, chronic bronchitis, chronic obstructive pulmonary disease (COPD), sinusitis, meningitis, conjunctivitis, endocarditis, prostatitis, tuberculosis, cellulitis, anthrax, plague, in veterinary medicine. The spectrum of action includes Gram-positive and Gram-negative bacteria: Bacillus anthracis, Enterobacter spp., Haemophilus influenzae, Klebsiella spp., Moraxella catarrhalis, Mycobacterium spp., Mycoplasma genitalium, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae. It works by inhibiting enzymes necessary to separate bacterial DNA, thereby inhibiting cell replication.
Amoxicillin, Clavulanate (Augmentin)
Ciprofloxacin (Ciloxan, Cipro)
Sulfamethoxazole, Trimethoprim (Bactrim)
Pharmacological and medical categories:
Anti infective agents
Anti tubercular drugs
Eye anti-infectives and antiseptics
Veterinary, pet meds
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01M - Quinolone antibacterials
J01MA - Fluoroquinolones
J01MA14 - Moxifloxacin
S - Sensory organs
S01 - Ophthalmologicals
S01A - Antiinfectives
S01AE - Fluoroquinolones
S01AE07 - Moxifloxacin
Tuberculosis - A15-A19
Plague - A20
Anthrax - A22
Meningitis due to other and unspecified causes - G03
Conjunctivitis - H10
Acute and subacute endocarditis - I33
Acute sinusitis - J01
Influenza and pneumonia - J09-J18
Bacterial pneumonia, not elsewhere classified - J15
Pneumonia, unspecified organism - J18
Chronic lower respiratory diseases - J40-J47
Unspecified chronic bronchitis - J42
Other chronic obstructive pulmonary disease - J44
Impetigo - L01
Cutaneous abscess, furuncle and carbuncle - L02
Cellulitis - L03
Other local infections of skin and subcutaneous tissue - L08
Inflammatory diseases of prostate - N41
Indications and usage:
Moxifloxacin (Avelox) is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below:
Community acquired pneumonia
Skin and skin structure infections: uncomplicated and complicated
Complicated intra-abdominal infections
Acute bacterial sinusitis
Acute bacterial exacerbation of chronic bronchitis
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Avelox and other antibacterial drugs. Moxifloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
Dosage and administration:
The dose of Moxifloxacin (Avelox) is 400 mg every 24 hours for all types of infection:
Community acquired pneumonia: 7–14 days
Uncomplicated skin and skin structure infections (SSSI): 7 days
Complicated SSSI: 7–21 days
Complicated intra-abdominal infections: 5–14 days
Plague: 10–14 days
Acute bacterial sinusitis: 10 days
Acute bacterial exacerbation of chronic bronchitis: 5 days
Dosage forms and strengt:
Avelox tablets: moxifloxacin hydrochloride (equivalent to 400 mg moxifloxacin).
Avelox injection: moxifloxacin hydrochloride (equivalent to 400 mg moxifloxacin) in 0.8% sodium chloride solution in a 250 mL flexibag.
Single oral overdoses up to 2.8 g of Moxifloxacin (Avelox) were not associated with any serious adverse events. In the event of acute overdose, empty the stomach and maintain adequate hydration. Monitor ECG due to the possibility of QT interval prolongation. Carefully observe the patient and give supportive treatment. The administration of activated charcoal as soon as possible after oral overdose may prevent excessive increase of systemic moxifloxacin exposure. About 3% and 9% of the dose of moxifloxacin, as well as about 2% and 4.5% of its glucuronide metabolite are removed by continuous ambulatory peritoneal dialysis and hemodialysis, respectively.
Known hypersensitivity to Avelox (Moxifloxacin) or other quinolones.
Warnings and precautions:
Prolongation of the QT interval and isolated cases of torsade de pointes has been reported. Avoid use in patients with known prolongation, proarrhythmic conditions such as clinically significant bradycardia or acute myocardial ischemia, hypokalemia, hypomagnesemia, and with drugs that prolong the QT interval.
Hypersensitivity and other serious reactions: serious and sometimes fatal reactions, including anaphylactic reactions, may occur after first or subsequent doses of Avelox. Discontinue Moxifloxacin at first sign of skin rash, jaundice or any other sign of hypersensitivity.
Clostridium difficile-associated diarrhea: evaluate if diarrhea occurs.
Adverse reactions, side effects:
Most common adverse reactions of moxifloxacin ( >= 3%) were nausea, diarrhea, headache, and dizziness.
To report suspected adverse reactions of Avelox, contact Bayer HealthCare Pharmaceuticals Inc. or your local FDA.
Multivalent cation-containing products (including antacids, sucralfate, multivitamins) decreased moxifloxacin absorption. Take Avelox tablet at least 4 hours before or 8 hours after these products.
Warfarin: anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding.
Class IA and Class III antiarrhythmics: proarrhythmic effect may be enhanced. Avoid concomitant use.
Antidiabetic agents: carefully monitor blood glucose.
Use in specific populations:
Pregnancy: based on animal data may cause fetal harm.
Geriatrics: increased risk for severe tendon disorders further increased by concomitant corticosteroid therapy and increased risk of prolongation of the QT interval.
B3 - Australia
C - United States (Risk cannot be ruled out)
Salts and other forms:
Synonyms, international and chemical names:
Brands, generics, trade names:
Actira - Bayer, BayCare
Apdrops - Ajanta Pharma
Avalox - Bayer
Avelox - Bayer
Izilox - Bayer
Mediflox - Medico Healthcare
Megaxin - Bayer, Perrigo
Milflox - Sun Pharmaceutical Industries
Moxeza - Alcon
Moxibact - Torrent Pharmaceuticals
Moxicip - Cipla
Moxigram - Micro Labs
Octegra - Bayer, Bago Laboratorios, Elpen, Grupo Vita / Vita Cientifica, Recordati
Proflox - Therabel Pharma
Vigamox - Alcon
Zymox - Zodley Pharmaceuticals
APIs used in medicine in combinations with moxifloxacin:
Here is a list of popular medications containing moxifloxacin as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:
|Trade name of the drug
||Pharmaceutical forms and doses
||Injectable; Infusion; Moxifloxacin Hydrochloride 400 mg / 250 mlTablets, Film-Coated; Oral; Moxifloxacin Hydrochloride 400 mg
||BayerB & S HealthcareBayHealth Comercializacao de Produtos FarmaceuticosDKSHFreseniusGen MedicineMaxxcareMerckZuellig Pharma
||Drops; Ophthalmic; Moxifloxacin Hydrochloride 0.5%Injectable; Infusion; Moxifloxacin Hydrochloride 400 mg / 250 mlInjectable; Infusion; Moxifloxacin Hydrochloride 400 mg / 100 mlOintment; Ophthalmic; Moxifloxacin Hydrochloride 0.5%Tablets, Film-Coated; Oral; Moxifloxacin Hydrochloride 400 mg
||Solution; Ophthalmic; Moxifloxacin Hydrochloride 0.5%
||AlconAlkem PharmaceuticalsDKSHFirma Chun CheongMedcor PharmaceuticalsMetro Drug DistributionNovartisSummitZuellig Pharma
Moxifloxacin main article on Wikipedia: https://en.wikipedia.org/wiki/Moxifloxacin
Moxifloxacin compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Moxifloxacin
Moxifloxacin Hydrochloride compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Moxifloxacin-hydrochloride
Moxifloxacin base on DrugBank: https://www.drugbank.ca/drugs/DB00218
Moxifloxacin Hydrochloride on DrugBank: https://www.drugbank.ca/salts/DBSALT000387
Moxifloxacin FAQ on MedlinePlus (revised 07/15/2019): https://medlineplus.gov/druginfo/meds/a600002.html
Moxifloxacin Ophthalmic FAQ on MedlinePlus (revised 06/15/2016): https://medlineplus.gov/druginfo/meds/a605016.html
Moxifloxacin Injection FAQ on MedlinePlus (revised 07/15/2019): https://medlineplus.gov/druginfo/meds/a608030.html
Avelox (Moxifloxacin Hydrochloride) film-coated tablets drug label info on DailyMed (revised August 8, 2011): https://dailymed.nlm.nih.gov/dailymed/lookup...
Moxifloxacin Hydrochloride film-coated tablets drug label info on DailyMed (revised December 9, 2020): https://dailymed.nlm.nih.gov/dailymed/lookup...
Moxifloxacin containing drugs on Drugs-About.com: https://drugs-about.com/ing/moxifloxacin.html
Moxifloxacin for sale on Pharma Doctor: https://pharma-doctor.com/moxifloxacin.html
Moxifloxacin international drug names on Drugs.com: https://www.drugs.com/international/moxifloxacin.html
Avelox (Moxifloxacin Hydrochloride) tablets and injection for intravenous use official prescribing information and medication guide from the U.S. FDA (revised 07/2016): https://www.accessdata.fda.gov/drugsatfda_docs/label...
Avelox (Moxifloxacin Hydrochloride) 400 mg tablets and Avelox I.V. injection 400 mg/250 mL (1.6 mg/mL) for intravenous use product monograph on Bayer pharmaceutical company website (revised February 18, 2020): https://www.bayer.ca/omr/online/avelox-pm-en.pdf
Vigamox (Moxifloxacin Hydrochloride) ophthalmic solution 0.5% prescribing information on Novartis pharmaceutical company website (revised 06/2020): https://www.pharma.us.novartis.com/sites/...
Moxicip (Moxifloxacin Hydrochloride) 400 mg film-coated tablets prescribing information on Cipla pharmaceutical company website (revised November 2018): https://ciplamed.com/content/moxicip-tablets
Moxifloxacin 400 mg film-coated tablets patient information leaflet on Medicines.org.uk (revised November 2020): https://www.medicines.org.uk/emc/files/pil.3273.pdf
Revised: June 2021
Home | Overview | Methodology | Respiratory Season Advice | General Conditions of Use | Legal Information | Privacy Statement | Contact Us
Copyright © 2001 - 2021 Respiratory Tract Infection Alert System by Bayer Corporation. All rights reserved.